...the cost per tumor detected was $7,692 for cystoscopy alone; $9,557 for cystoscopy with Inverness' NMP22 BladderChek Test...
...Oncology Genitourinary Cancers Symposium in San Francisco. Inverness Medical Innovations Inc. (NYSE:IMA), Waltham, Mass. Product: NMP22 BladderChek Test...

...deal was announced. MZT also is eligible for $2 million in revenue milestones. MZT markets NMP22 BladderChek Test...

...specificity of NMP22 assay was 49.5% and 87.3%, respectively. Matritech Inc. (MZT), Newton, Mass. Product: NMP22 BladderChek Test...

...BladderChek is approved in the U.S., Europe and Canada. Matritech Inc. (MZT), Newton, Mass. Product: NMP22 BladderChek Test...

...In a U.S. study in 1,331 patients at risk for bladder cancer, the NMP22 BladderChek test with cytoscopy...
...89% seen by cytoscopy alone (p=0.26). Of the 79 patients diagnosed with bladder cancer, the NMP22 test...
...patients with 15.8% sensitivity with cytoscopy alone. The cytoscopy alone was significantly more specific vs. NMP22 test...

...Matritech Inc. (MZT), Newton, Mass. Product: NMP22 BladderChek Business: Diagnostic Health Canada approved NMP22 BladderChek, an...
...Stellar International Inc. (TSXV:SLX, London, Ontario) has exclusive rights to market the assay in Canada. BladderChek...

...to hospitals and clinical reference laboratories in the U.S. MZT will continue to sell the NMP22 BladderChek test...

...MZT received CE Mark approval in the EU for its NMP22 products, including NMP22 BladderChek to...

...The company markets Quadramet for cancer bone pain, ProstaScint imaging agent for prostate cancer and BladderChek...

...company SSY received exclusive rights to market NMPS's NMP22 BladderChek test to diagnose and monitor bladder cancer. BladderChek...